337 related articles for article (PubMed ID: 33021139)
1. Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Varnai R; Sipeky C
Pharmacogenomics; 2020 Oct; 21(15):1101-1115. PubMed ID: 33021139
[TBL] [Abstract][Full Text] [Related]
2. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
Shore N; Ionescu-Ittu R; Yang L; Laliberté F; Mahendran M; Lejeune D; Yu L; Burgents J; Duh MS; Ghate SR
Future Oncol; 2021 Aug; 17(22):2907-2921. PubMed ID: 33906368
[TBL] [Abstract][Full Text] [Related]
3. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
4. Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity.
Sokolova AO; Yu EY; Cheng HH
Clin Cancer Res; 2020 Jun; 26(11):2439-2440. PubMed ID: 32234758
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in castration-resistant prostate cancer.
Tripathi A; Balakrishna P; Agarwal N
Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972
[TBL] [Abstract][Full Text] [Related]
6. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
Castro E; Mateo J; Olmos D; de Bono JS
Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
[TBL] [Abstract][Full Text] [Related]
7. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
Bieńkowski M; Tomasik B; Braun M; Jassem J
Cancer Treat Rev; 2022 Mar; 104():102359. PubMed ID: 35190335
[TBL] [Abstract][Full Text] [Related]
9. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
10. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Su CT; Nizialek E; Berchuck JE; Vlachostergios PJ; Ashkar R; Sokolova A; Barata PC; Aggarwal RR; McKay RR; Agarwal N; McClure HM; Nafissi N; Bryce AH; Sartor O; Sayegh N; Cheng HH; Adra N; Sternberg CN; Taplin ME; Cieslik M; Alva AS; Antonarakis ES
Prostate; 2023 Feb; 83(3):227-236. PubMed ID: 36382533
[TBL] [Abstract][Full Text] [Related]
11. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Abida W; Campbell D; Patnaik A; Shapiro JD; Sautois B; Vogelzang NJ; Voog EG; Bryce AH; McDermott R; Ricci F; Rowe J; Zhang J; Piulats JM; Fizazi K; Merseburger AS; Higano CS; Krieger LE; Ryan CJ; Feng FY; Simmons AD; Loehr A; Despain D; Dowson M; Green F; Watkins SP; Golsorkhi T; Chowdhury S
Clin Cancer Res; 2020 Jun; 26(11):2487-2496. PubMed ID: 32086346
[TBL] [Abstract][Full Text] [Related]
12. Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.
Rescigno P; Chandler R; de Bono J
Curr Opin Support Palliat Care; 2018 Sep; 12(3):339-343. PubMed ID: 29979319
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Xu C; Mao S; Jiang H
Methods Mol Biol; 2020; 2204():75-89. PubMed ID: 32710316
[TBL] [Abstract][Full Text] [Related]
14. Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer.
Mouw KW; Choudhury AD
Cancer Treat Res; 2023; 186():103-124. PubMed ID: 37978133
[TBL] [Abstract][Full Text] [Related]
15. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
[No Abstract] [Full Text] [Related]
16. Precision Medicine in Castration-Resistant Prostate Cancer: Advances, Challenges, and the Landscape of PARPi Therapy-A Narrative Review.
Dimitrov G; Mangaldzhiev R; Slavov C; Popov E
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396858
[TBL] [Abstract][Full Text] [Related]
17. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.
Iannantuono GM; Chandran E; Floudas CS; Choo-Wosoba H; Butera G; Roselli M; Gulley JL; Karzai F
Cancer Treat Rev; 2023 Nov; 120():102623. PubMed ID: 37716332
[TBL] [Abstract][Full Text] [Related]
19. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
Sigorski D; Iżycka-Świeszewska E; Bodnar L
Target Oncol; 2020 Dec; 15(6):709-722. PubMed ID: 33044685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
